ROCA Test® For Early Detection of Ovarian Cancer Is Now Available In Quad Cities
Women in the Quad Cities now have access to one of the most advanced tools for early detection of ovarian cancer.
Abcodia, a clinical stage company developing novel tests for the early detection of cancer, has announced the availability of the ROCA Test® for use in 43 states, including Illinois and Iowa.
The ROCA Test® uses a number of clinical variables such as age, menopausal status and serial blood measurements of biomarker protein, CA-125, to assess the likelihood that a woman has ovarian cancer. The ROCA Test® is the first step in a multimodal assessment for ovarian cancer and can be used to help physicians assess whether a woman should undergo additional testing, including transvaginal ultrasound scan of the ovaries.
The ROCA Test® is intended for post-menopausal women ages 50 to 85 with no known ovarian cancer risk factors. The test can also be used with women 35 to 85 who are considered to be at high risk of ovarian cancer because of family history of ovarian or breast cancer, or a mutation in specific genes such as BRCA1 and BRCA2 or Lynch Syndrome genes.
In a 15-year clinical trial involving 50,640 post-menopausal women, the ROCA Test® accurately detected 85.8% of ovarian cancers by comparing a patient’s blood marker profile to known profiles of women with and without ovarian cancer.
“This is an important advancement for earlier diagnosis of ovarian cancer, which often is only detected when the cancer has already advanced to a later stage,’’ said Jodie Kavensky, founder and CEO of the NormaLeah Ovarian Cancer Initiative, a Quad-Cities advocate for improved screening and detection of ovarian cancer.
“This test was introduced in December 2015 and we are fortunate in Illinois and Iowa, and now throughout the Quad Cities, to have access to the ROCA Test®.’’
Cost of the test for normal risk patients is $295 once each year. For high risk patients, three tests per year are recommended at a cost of $885. The test is not currently covered by Medicare or other federal healthcare programs, or by any commercial insurance company. The cost of the test is the patient's responsibility. A physician order is necessary to order the test.
Each year, about 22,000 women in the United States receive a diagnosis of ovarian cancer. Among women in the United States, ovarian cancer is the eighth most common cancer and the fifth-leading cause of cancer death, after lung and bronchus, breast, colorectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but it accounts for only about 3% of all cancers in women. The survival rate past five years is currently less than 50%. When ovarian cancer is found in its early stages, treatment is most effective and the survival rate soars.
ABOUT NORMALEAH FOUNDATION OVARIAN CANCER INITIATIVE:
The NormaLeah Ovarian Cancer Foundation is a 501(c) 3 organization established to create public awareness, promote early detection, and support research for ovarian cancer. The ultimate goal is to have ovarian cancer screening become a routine part of a woman’s annual gynecological exam. The foundation honors the memory of two sisters, Norma Yecies Shagrin (May 21, 1935 – June 1, 2008) and Leah Yecies Hantman (July 25, 1931 – August 21, 1998) whose lives were cut short by this deadly disease.